payer relationships

By Michelle Vitko, Senior Research Analyst Preparing to present data to managed care stakeholders is often health outcomes liaisons' (HOLs) most time-intensive activity. While the exact breakdown of time investment varies from company to company, most...

By Shaylyn Pike, Senior Research Analyst The managed markets function in the United States has been around for many years. Since the arrival of Medicare, Medicaid and the health insurance industry in its current form, drug and device companies have...

By Shaylyn Pike,Senior Research Analyst Once upon a time, a brand team's quest ended at marketing approval; revenues would take care of themselves. Fast forward 20 years, and the industry faces a much more challenging road to brand success. Receiving...

Drug companies allocated 13 percent of their average total market access budgets to patient-reported outcomes teams this year, according to new benchmarking data from Cutting Edge Information. 57 percent of profiled companies will increase their PRO team budgets...

Our recent study of Phase IV Trials found that post-marketing studies are increasingly "regionalized" to better meet U.S. and European market requirements. Differences in what regulators and payers are looking for in post-approval information in Europe and...

By Jeremy Spivey,Senior Research Analyst Preliminary survey results from our ongoing portfolio management study have already revealed some interesting details. Among them: * Government payer reimbursement rates for products are Continue reading “Portfolio...

The most important consideration for any corporate team is its customers. While serving targeted payers is the stated goal of practically every market access teams' strategy, many groups fail to incorporate and reflect payer demands and value-adds in their strategic...

Dendreon, maker of Provenge, the first autologous cellular immunosuppressant treatment for cancer, has hit a roadblock: it has not met its forecasted earnings. Analysts say that this is most likely due to problems getting reimbursed. Payers are reluctant to...

The cost of running a comparative effectiveness trial is $13,087 per patient during Phase IV, according to our newest Medical Affairs and Market Access research. Comparative Effectiveness Research (CER) compares drugs, devices or other medical tests and procedures...

New research finds pharma pricing teams gaining strategic importance and greater resources. The average cost for pricing activities supporting innovative drugs is $974,000 from Phase I through a brand’s second year on the market, according to research in our...